When was ESCAPE Bio founded?

ESCAPE Bio was founded in 2015 and raised its 1st funding round 2 years after it was founded.

Where is ESCAPE Bio located?

ESCAPE Bio is headquartered in San Francisco, United States.

Who is the current CEO of ESCAPE Bio?

Julie Anne Smith of ESCAPE Bio.

Is ESCAPE Bio a funded company?

ESCAPE Bio is a funded company, having raised a total of $167M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jul 12, 2017.

When was the latest funding round of ESCAPE Bio?

ESCAPE Bio's latest funding was a $***** Series C round on Sep 14, 2020, with participation from 12 investors.

Where does ESCAPE Bio rank among its competitors?

ESCAPE Bio ranks 75th amongst 212 active competitors, of which 63 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was LEXEO Therapeutics, which secured $10M in Oct, 2025.

Who are the top competitors of ESCAPE Bio?

ESCAPE Bio's top competitors include Enliven Therapeutics, Rigel and Q32 Bio. Among them, LEXEO Therapeutics secured the most recent funding round in October, 2025.

ESCAPE Bio - 2026 Company Profile, Team, Funding & Competitors

ESCAPE Bio is a deadpooled company based in San Francisco (United States), founded in 2015. It operates as a Developer of therapeutic solutions for treating genetic neurodegenerative diseases. ESCAPE Bio has raised $167M in funding from investors like Orbimed, Sutter Hill Ventures and New Leaf Venture Partners. The company has 212 active competitors, including 63 funded and 38 that have exited. Its top competitors include companies like Enliven Therapeutics, Rigel and Q32 Bio.

Company Details

ESCAPE Bio is a developer of therapeutic solutions for treating genetic neurodegenerative diseases. It provides drugs for people suffering from Alzheimer's disease, Parkinson's disease, and CNS lysosomal storage disorders. It has developed ESB1609 that is a small molecule S1P5 receptor agonist for the treatment of CNS lysosomal storage disorders. It also offers the ESB5070 drug that is a small molecule kinase inhibitor for Parkinson’s disease patients who have an LRRK2 G2019S variant and an Alzheimer's disease.

Website: escapebio.com
Email ID: *****@escapebio.com
Phone Number: +1 **********

Key Metrics

Founded Year

2015

Location

San Francisco, United States

Stage

Deadpooled

Total Funding

$167M in 3 rounds

Latest Funding Round

Series C, Sep 14, 2020, $*****

Investors

Orbimed & 14 more

Ranked

75^th among 212 active competitors

Similar Companies

Enliven Therapeutics & 221 more

View ESCAPE Bio's full profile

ESCAPE Bio has raised a total funding of $167M over 3 rounds. Its first funding round was on Jul 12, 2017. Its latest funding round was a Series C round on Sep 14, 2020 for $*****. 12 investors participated in its latest round. ESCAPE Bio has 15 institutional investors.

Here is the list of recent funding rounds of ESCAPE Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 14, 2020	4542605	Series C	4990045	6825839	2360937	5309617
Jul 29, 2019	6011737	Series A	7232725	6773185	5959432	7138893
Jul 12, 2017	5415860	Series A	4974760	2223715	Orbimed	Novo Holdings & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of ESCAPE Bio's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ESCAPE Bio include Enliven Therapeutics, Rigel and Q32 Bio. Here is the list of Top 10 competitors of ESCAPE Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Enliven Therapeutics 2019, Boulder (United States), Public	Developer of drugs for solid tumours and blood cancers	$140M	Orbimed, Surveyor Capital & 15 others	67/100
2nd	Rigel 1996, San Francisco (United States), Public	Developer of drugs for hematologic disorders, cancer, and rare immune disease	-	MPM Capital, MidCap Financial & 6 others	64/100
3rd	Q32 Bio 2018, Cambridge (United States), Public	Developer of drugs for treating autoimmune disorders	$106M	Orbimed, Acorn Bioventures & 9 others	64/100
4th	Drug Farm 2015, Shanghai (China), Series C	Developer of a novel treatment for metabolic diseases	$83M	Zhejiang Private Enterprise United Investment, BioVeda China Fund ... & 7 others	63/100
5th	Alzheon 2013, Framingham (United States), Series E	Developer of disease-modifying treatments for Alzheimer's disease and other neurodegenerative disorders	$195M	Ally Bridge Group, Alerce Medical Technology Partners ... & 4 others	62/100
6th	LEXEO Therapeutics 2018, New York City (United States), Public	Developer of gene therapy for the treatment of CLN2 Batten and Alzheimer's diseases	$185M	Eventide Funds, Omega Funds & 26 others	61/100
7th	RUBEDO LIFE SCIENCES 2018, Sunnyvale (United States), Series A	Developer of therapeutics for age-related diseases	$52M	Khosla Ventures, Ahren & 11 others	61/100
8th	Nuvalent 2017, Cambridge (United States), Public	Developer of therapeutic solutions for the treatment of cancer	$185M	Bain Capital Life Sciences, Deerfield & 10 others	61/100
9th	Abbisko Therapeutics 2016, Shanghai (China), Public	Developing novel small molecule drugs for immunomodulatory pathways to treat cancer	$263M	Lilly Asia Ventures, Temasek & 15 others	60/100
10th	NewAmsterdam Pharma 2019, Naarden (Netherlands), Public	Developer of transformative therapeutic solutions for cardio-metabolic diseases	$196M	Morningside, Forbion & 11 others	59/100
75th	ESCAPE Bio 2015, San Francisco (United States), Deadpooled	Developer of therapeutic solutions for treating genetic neurodegenerative diseases	$167M	Wellington, CAM Capital & 13 others	34/100